Alzheimer’s Disease Research Alliance Reaches Key Milestone

Alzheimer’s Disease Research Alliance Reaches Key Milestone
Evotec AG has reached an important milestone concerning its TargetAD partnership with Janssen Pharmaceuticals for the transition of a product into further drug discovery process. Even though the announcement was made this year, the milestone was reached in 2015. Evotec’s TargetAD database is a customized system to provide unique information on the connection between molecular and cellular changes in brain tissue with Alzheimer’s disease (AD) progression. The database was developed during a multiyear research program, applying cellular, histological, and living tissue target validation procedures, providing a strong platform for comprehensive and systematic target identification and validation, as well as compound discovery programs. According to the agreement established in 2013, Evotec and Janssen are committed to collaborate in the development of novel drugs for AD, and Johnson & Johnson Innovation facilitates the collaboration. Janssen is currently funding target drug discovery research by combining defined research payments with milestones related to progress. The company reserves the right to internalize selected targets and therapeutic candidates to move them into pre-clinical and clinical development. Evotec AG is a worldwide-operating company focused on fast-progressing innovative product approaches, with global pharmaceuticals and biotech companies, scholars, patient advocacy groups and venture capitalists in its group. Previous collaborations include Roche, in Alzheimer’s disease research, or Janssen Pharma, in the field of depression. "Despite the significant challenges in identifying and pros
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *